Neurology of Sleep

Ahmad, Samiya; Buckley, Ashura; Glaze, Daniel G.

doi:10.1016/j.ncl.2021.04.007

Cited by 9 publications

(5 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is alarming, since adequate sleep, both in quantity and quality, is important for childrens' health and development [2]. In children who attend primary school (8-12 years), sleep is crucial for the development of physical, cognitive and social performance such as learning, repair and memory consolidation [3]. The period at secondary school (12-19 years) is considered a vulnerable period for sleep due to the signi cant changes in physiology children go through [4].…”

Section: Introductionmentioning

confidence: 99%

Self-reported quantity and quality of sleep in children and adolescents with a chronic condition compared to healthy controls

Biemans

Nijhof

Gorter

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To assess self-reported quantity and quality of sleep in Dutch children with a chronic condition compared to healthy controls, compared to the recommended hours of sleep for youth. Methods Sleep quantity and quality were analyzed in children with a chronic condition (cystic fibrosis, chronic kidney disease, congenital heart disease, (auto-)immune disease, and medically unexplained symptoms (MUS); N = 291; 15 ± 3.1 years, 63.1% female. A subset of 171 children with a chronic condition were matched to healthy controls using Propensity Score matching, based on age and sex, ratio 1:4. Self-reported sleep quantity and quality were assessed with established questionnaires. Children with MUS were analyzed separately to distinguish between chronic conditions with and without an identified pathophysiological cause. Results Generally, children with a chronic condition met the recommended amount of sleep, however 22.3% reported poor sleep quality. No significant differences in sleep quantity and quality were found between the diagnosis groups. Children with a chronic condition and with MUS slept significantly more than healthy controls at ages 13, 15, and 16. Both at primary and secondary school, poor sleep quality was least frequent reported in children with a chronic condition and most often reported in children with MUS. Conclusions Overall, children with chronic conditions, including MUS, met the recommended hours of sleep for youth, and slept more than healthy controls. However, it is important to obtain a better understanding of why a substantial subset of children with chronic conditions, mostly children with MUS, still perceived their sleep quality as poor.

show abstract

Section: Introductionmentioning

confidence: 99%

Self-reported quantity and quality of sleep in children and adolescents with a chronic condition compared to healthy controls

Biemans

Nijhof

Gorter

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…This is alarming, since adequate sleep, both in quantity and quality, is important for childrens’ health and development [ 2 ]. In children who attend primary school (8–12 years), sleep is crucial for the development of physical, cognitive and social performance such as learning, repair and memory consolidation [ 3 ]. The period at secondary school (12–19 years) is considered a vulnerable period for sleep due to the significant changes in physiology children go through [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Self-reported quantity and quality of sleep in children and adolescents with a chronic condition compared to healthy controls

et al. 2023

View full text Add to dashboard Cite

To assess self-reported quantity and quality of sleep in Dutch children with a chronic condition compared to healthy controls and to the recommended hours of sleep for youth. Sleep quantity and quality were analyzed in children with a chronic condition (cystic fibrosis, chronic kidney disease, congenital heart disease, (auto-)immune disease, and medically unexplained symptoms (MUS); n = 291; 15 ± 3.1 years, 63% female. A subset of 171 children with a chronic condition were matched to healthy controls using Propensity Score matching, based on age and sex, ratio 1:4. Self-reported sleep quantity and quality were assessed with established questionnaires. Children with MUS were analyzed separately to distinguish between chronic conditions with and without an identified pathophysiological cause. Generally, children with a chronic condition met the recommended amount of sleep, however 22% reported poor sleep quality. No significant differences in sleep quantity and quality were found between the diagnosis groups. Children with a chronic condition and with MUS slept significantly more than healthy controls at ages 13, 15, and 16. Both at primary and secondary school, poor sleep quality was least frequent reported in children with a chronic condition and most often reported in children with MUS. Conclusion: Overall, children with chronic conditions, including MUS, met the recommended hours of sleep for youth, and slept more than healthy controls. However, it is important to obtain a better understanding of why a substantial subset of children with chronic conditions, mostly children with MUS, still perceived their sleep quality as poor. What is Known:• According to the Consensus statement of the American Academy of Sleep medicine, typically developing children (6 to 12 years) should sleep 9 to 12 h per night, and adolescents (13 to 18 years) should sleep 8 to 10 h per night.• Literature on the optimal quantity and quality of sleep in children with a chronic condition is very limited. What is New:Our findings are important and provide novel insights:• In general, children with a chronic condition sleep according to the recommended hours of sleep.• A substantial subset of children with chronic conditions, perceived their sleep quality as poor. Although this was reported mostly by children with medically unexplained symptoms (MUS), the found poor sleep quality was independent of specific diagnosis.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Sleep is a complex process, regulated by circadian and homeostatic processes, and influenced by genetic and environmental factors ( Ahmad et al, 2021 ). Sleep disorders, including apneas, insomnia, narcolepsy, parasomnias, and circadian rhythm disorders, are prevalent and can seriously affect patients’ quality of life ( Ramar and Olson, 2013 ; Ahmad et al, 2021 ). Common treatment options for insomnia include hypnotics like benzodiazepines, while in the case of narcolepsy sedatives like sodium oxybate, that improve nighttime sleep or amphetamine-like psychostimulants that improve daytime wakefulness are typically used.…”

Section: Introductionmentioning

confidence: 99%

Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor

Pardon

Claes²,

Druwé³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

New pharmacological approaches that target orexin receptors (OXRs) are being developed to treat sleep disorders such as insomnia and narcolepsy, with fewer side effects than existing treatments. Orexins are neuropeptides that exert excitatory effects on postsynaptic neurons via the OXRs, and are important in regulating sleep/wake states. To date, there are three FDA-approved dual orexin receptor antagonists for the treatment of insomnia, and several small molecule oral OX2R (OXR type 2) agonists are in the pipeline for addressing the orexin deficiency in narcolepsy. To find new hypnotics and psychostimulants, rodents have been the model of choice, but they are costly and have substantially different sleep patterns to humans. As an alternative model, zebrafish larvae that like humans are diurnal and show peak daytime activity and rest at night offer several potential advantages including the ability for high throughput screening. To pharmacologically validate the use of a zebrafish model in the discovery of new compounds, we aimed in this study to evaluate the functionality of a set of known small molecule OX2R agonists and antagonists on human and zebrafish OXRs and to probe their effects on the behavior of zebrafish larvae. To this end, we developed an in vitro IP-One Homogeneous Time Resolved Fluorescence (HTRF) immunoassay, and in vivo locomotor assays that record the locomotor activity of zebrafish larvae under physiological light conditions as well as under dark-light triggers. We demonstrate that the functional IP-One test is a good predictor of biological activity in vivo. Moreover, the behavioral data show that a high-throughput assay that records the locomotor activity of zebrafish throughout the evening, night and morning is able to distinguish between OXR agonists and antagonists active on the zebrafish OXR. Conversely, a locomotor assay with alternating 30 min dark-light transitions throughout the day is not able to distinguish between the two sets of compounds, indicating the importance of circadian rhythm to their pharmacological activity. Overall, the results show that a functional IP-one test in combination with a behavioral assay using zebrafish is well-suited as a discovery platform to find novel compounds that target OXRs for the treatment of sleep disorders.

show abstract

Neurology of Sleep

Cited by 9 publications

References 37 publications

Self-reported quantity and quality of sleep in children and adolescents with a chronic condition compared to healthy controls

Self-reported quantity and quality of sleep in children and adolescents with a chronic condition compared to healthy controls

Self-reported quantity and quality of sleep in children and adolescents with a chronic condition compared to healthy controls

Modulation of sleep behavior in zebrafish larvae by pharmacological targeting of the orexin receptor

Contact Info

Product

Resources

About